BioStem Technologies (OTCMKTS:BSEM) versus HCW Biologics (NASDAQ:HCWB) Head-To-Head Survey

HCW Biologics (NASDAQ:HCWB) and BioStem Technologies (OTCMKTS:BSEM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.

Earnings & Valuation

This table compares HCW Biologics and BioStem Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50,000.00	69.89	-$7.96 million	($27.60)	-0.06
BioStem Technologies	$292.21 million	0.15	-$28.70 million	($1.60)	-1.49

HCW Biologics has higher earnings, but lower revenue than BioStem Technologies. BioStem Technologies is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for HCW Biologics and BioStem Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1	0	1	0	2.00
BioStem Technologies	0	1	0	1	3.00

HCW Biologics currently has a consensus price target of $30.00, suggesting a potential upside of 1,823.08%. BioStem Technologies has a consensus price target of $9.00, suggesting a potential upside of 276.57%. Given HCW Biologics’ higher possible upside, research analysts plainly believe HCW Biologics is more favorable than BioStem Technologies.

Profitability

This table compares HCW Biologics and BioStem Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
BioStem Technologies	N/A	N/A	N/A

Institutional & Insider Ownership

3.0% of HCW Biologics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

HCW Biologics has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500. Comparatively, BioStem Technologies has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500.

Summary

HCW Biologics beats BioStem Technologies on 8 of the 15 factors compared between the two stocks.

About HCW Biologics

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

About BioStem Technologies

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.